
Revive Therapeutics Ltd.
Consolidated Financial Statements
Years Ended June 30, 2020 and 2019
(Expressed in Canadian Dollars)



INDEPENDENT AUDITOR'S REPORT

To the Shareholders of
Revive Therapeutics Ltd.

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Revive Therapeutics Ltd. (the Company), which comprise the consolidated statements of financial position as at June 30, 2020 and the consolidated statements of loss and comprehensive loss, consolidated statements of changes in equity and consolidated statements of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as at June 30, 2020 and its financial performance and its cash flows for the year then ended, in accordance with International Financial Reporting Standards.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with those requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material Uncertainty Relating to Going Concern

We draw your attention to Note 1 in the consolidated financial statements, which indicates the Company incurred a comprehensive loss of \$5,381,686 during the year ended June 30, 2020. As stated in Note 1, these events or conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Other Matter

The financial statements of the Company for the year ended June 30, 2019, were audited by another auditor, who expressed an unmodified opinion on those financial statements on October 22, 2019.

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

Management is responsible for the other information. The other information comprises the annual management's discussion and analysis, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements. As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner on the audit resulting in this independent auditor's report is Pat Kenney.

Clearhouse LLP

Chartered Professional Accountants
Licensed Public Accountants

Mississauga, Ontario
October 28, 2020

Revive Therapeutics Ltd.
Consolidated Statements of Financial Position
(Expressed in Canadian dollars)

	June 30, 2020	June 30, 2019
ASSETS		
Current assets		
Cash and cash equivalents	\$ 1,381,483	\$ 475,234
HST receivable	100,790	-
Lease receivable (note 6)	76,763	-
Prepaid expenses	499,212	53,090
Investments (note 7)	100,000	-
Total current assets	2,158,248	528,324
Non-current assets		
Investments (note 7)	250,000	750,000
Equipment (note 9)	3,191	4,230
Lease receivable (note 6)	349,141	-
Intangible asset (note 8)	5,500,000	-
Total non-current assets	6,102,332	754,230
Total assets	\$ 8,260,580	\$ 1,282,554
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued liabilities (notes 11 and 22)	\$ 302,186	\$ 321,772
Lease liability (note 13)	70,014	-
Total current liabilities	372,200	321,772
Non-current liabilities		
Lease liability (note 13)	355,840	-
Statute barred liabilities (note 12)	63,511	-
Loan payable (note 15)	40,000	-
Total liabilities	831,551	321,772
Shareholders' equity		
Share capital (note 16)	19,126,095	9,352,491
Warrants and broker and finder warrants (notes 17 and 18)	1,403,051	430,370
Contributed surplus (note 19)	3,220,931	2,117,282
Accumulated deficit	(16,321,048)	(10,939,361)
Total shareholders' equity	7,429,029	960,782
Total liabilities and shareholders' equity	\$ 8,260,580	\$ 1,282,554

Nature of operations and going concern (note 1)

Commitments and contingency (note 23)

Subsequent events (note 25)

Approved on behalf of the Board:

"Michael Frank", Director

"Andrew Lindzon", Director

The accompanying notes to the consolidated financial statements are an integral part of these statements.

Revive Therapeutics Ltd.
Consolidated Statements of Comprehensive Loss
(Expressed in Canadian dollars)

Year Ended June 30,	2020	2019
Expenses		
Research costs	\$ 455,089	\$ 124,808
Salaries and benefits (note 22(b))	158,218	593,616
Stock-based compensation (notes 19 and 22(b))	1,191,320	133,230
Office expenses (note 24)	616,887	99,598
Consulting fees	942,808	42,767
Professional fees (note 22(a)(i)(ii))	266,704	285,727
Rent	26,440	33,554
Depreciation and amortization (notes 8, 9 and 10)	28,265	3,201
Comprehensive loss before the below items:	\$ 3,685,731	\$ 1,316,501
Accretion of lease liability (note 13)	75,543	-
Accretion of convertible debenture (note 14)	6,029	-
Interest expense on convertible debenture	6,084	-
Loss on sub-lease (note 2)	9,038	-
Finance income on sub-lease (note 6)	(47,595)	-
Loss on conversion of convertible debenture (note 14)	1,194,097	-
Gain on disposition of investments (note 7)	(44,740)	-
Unrealized loss on investments	497,500	-
Write-off of intangible asset	-	27,385
Comprehensive loss for the year	\$ (5,381,687)	\$ (1,343,886)
Comprehensive loss per share - basic and diluted (note 20)	\$ (0.05)	\$ (0.02)
Weighted average common shares outstanding - basic and diluted	106,877,828	63,969,666

The accompanying notes to the consolidated financial statements are an integral part of these statements.

Revive Therapeutics Ltd.
Consolidated Statements of Cash Flows
(Expressed in Canadian dollars)

Year Ended June 30,	2020	2019
Cash flow from operating activities		
Comprehensive loss for the period	\$ (5,381,687)	\$ (1,343,886)
Adjustments for:		
Depreciation and amortization	28,265	3,201
Stock-based compensation	1,191,320	133,230
Write-off of intangible assets	-	27,385
Loss on conversion of convertible debenture	1,194,097	-
Settlement of trade debt through issuance of shares	453,550	-
Accretion of lease liability	75,543	-
Loss on sub-lease	9,038	-
Accretion of convertible debenture	6,029	-
Interest expense on convertible debenture	6,084	-
Gain on disposition of investments	(44,740)	-
Unrealized loss on investments	497,500	-
Finance income on sub-lease	(47,595)	-
Net change in non-cash working capital:		
HST receivables	(100,790)	-
Prepaid expenses	(446,122)	(27,320)
Accounts payable and accrued liabilities	43,924	22,472
Net cash and cash equivalents used in operating activities	(2,515,584)	(1,184,918)
Investing activities		
Purchase of investment	-	(750,000)
Purchase of equipment	-	(685)
Proceeds from sale of investment	142,240	-
Net cash and cash equivalents used in investing activities	142,240	(750,685)
Financing activities		
Proceeds from issuance of shares, warrants and stock options	3,392,910	1,350,321
Share issuance costs	(294,855)	-
Lease payments	(136,181)	-
Proceeds from sublease	72,319	-
Proceeds from issuance of convertible debenture	205,400	-
Proceeds from loan payable	40,000	-
Net cash and cash equivalents provided by financing activities	3,279,593	1,350,321
Net change in cash and cash equivalents	906,249	(585,282)
Cash and cash equivalents, beginning of year	475,234	1,060,516
Cash and cash equivalents, end of year	\$ 1,381,483	\$ 475,234
Supplemental cash flow information		
Common shares issued for intangible asset	\$ 5,500,000	\$ -
Common shares issued for investment	\$ 195,000	\$ -
Common shares issued for debt settlement	\$ 453,550	\$ -
Common shares issued for conversion of convertible debenture	\$ 1,386,662	\$ -

The accompanying notes to the consolidated financial statements are an integral part of these statements.

Revive Therapeutics Ltd.
Consolidated Statements of Changes in Shareholders' Equity
(Expressed in Canadian dollars)

	Share capital		Equity portion of convertible debenture	Shares to be issued	Warrants and broker and finder warrants	Contributed surplus	Accumulated deficit	Total shareholders' equity
	Number of shares	Amount						
Balance, June 30, 2018	58,351,282	\$ 8,423,540	\$ -	\$ 9,000	\$ -	\$ 1,984,052	\$ (9,595,475)	\$ 821,117
Common shares issued in private placement (note 16(b)(i)(ii))	14,010,000	1,401,000	-	-	-	-	-	1,401,000
Valuation of warrants issued in private placement (note 16(b)(i)(ii))	-	(444,452)	-	-	444,452	-	-	-
Valuation of finder warrants issued in private placement (note 16(b)(i))	-	(1,954)	-	-	1,954	-	-	-
Transaction costs in private placements (note 16(b)(i)(ii))	-	(34,643)	-	-	(16,036)	-	-	(50,679)
Common shares issued for exercise of warrants	50,000	9,000	-	(9,000)	-	-	-	-
Stock-based compensation (note 19)	-	-	-	-	-	133,230	-	133,230
Comprehensive loss for the year	-	-	-	-	-	-	(1,343,886)	(1,343,886)
Balance, June 30, 2019	72,411,282	\$ 9,352,491	\$ -	\$ -	\$ 430,370	\$ 2,117,282	\$ (10,939,361)	\$ 960,782

The accompanying notes to the consolidated financial statements are an integral part of these statements.

Revive Therapeutics Ltd.

Consolidated Statements of Changes in Shareholders' Equity (continued)

(Expressed in Canadian dollars)

	Share capital		Equity portion of convertible debenture	Shares to be issued	Warrants and broker and finder warrants	Contributed surplus	Accumulated deficit	Total shareholders' equity
	Number of shares	Amount						
Balance, June 30, 2019	72,411,282	\$ 9,352,491	\$ -	\$ -	\$ 430,370	\$ 2,117,282	\$ (10,939,361)	\$ 960,782
Common shares issued in private placement (note 16(b)(iii)(v))	49,935,000	2,496,750	-	-	-	-	-	2,496,750
Valuation of warrants issued in private placement (note 16(b)(iii)(v))	-	(956,502)	-	-	956,502	-	-	-
Valuation of finder warrants issued in private placement (note 16(b)(iii)(v))	-	(280,068)	-	-	280,068	-	-	-
Transaction costs in private placements (note 16(b)(iii)(v))	-	(167,725)	-	-	(127,131)	-	-	(294,856)
Shares issued in settlement of debt (note 16(b)(vi))	9,062,495	453,550	-	-	-	-	-	453,550
Equity portion of convertible debenture (note 14)	-	-	34,962	-	-	-	-	34,962
Conversion of convertible debenture (note 14)	4,368,000	1,386,662	(34,962)	-	-	-	-	1,351,700
Warrants issued in convertible debenture (note 14)	-	-	-	-	25,348	-	-	25,348
Common shares issued for intangible asset (note 8)	55,000,000	5,500,000	-	-	-	-	-	5,500,000
Common shares issued for investment (note 16(b)(iv))	3,000,000	195,000	-	-	-	-	-	195,000
Common shares issued for exercise of warrants	5,220,734	943,262	-	-	(160,152)	-	-	783,110
Common shares issued for exercise of broker warrants	42,000	8,254	-	-	(1,954)	-	-	6,300
Common shares issued for exercise of stock options	850,000	194,421	-	-	-	(87,671)	-	106,750
Stock-based compensation (note 19)	-	-	-	-	-	1,191,320	-	1,191,320
Comprehensive loss for the year	-	-	-	-	-	-	(5,381,687)	(5,381,687)
Balance, June 30, 2020	199,889,511	\$ 19,126,095	\$ -	\$ -	\$ 1,403,051	\$ 3,220,931	\$ (16,321,048)	\$ 7,429,029

The accompanying notes to the consolidated financial statements are an integral part of these statements.

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements

For the Years Ended June 30, 2020 and 2019

(Expressed in Canadian dollars)

1. Nature of Operations and Going Concern

Revive Therapeutics Ltd. (the "Company" or "Revive") was incorporated under the Business Corporations Act (Ontario) on March 27, 2012. The Company's shares traded on the TSX Venture Exchange (the "Exchange") under the symbol "RVV" and the Frankfurt Stock Exchange in Germany under the symbol "31R". Revive also trades in the United States under pink sheets as RVVTF. The company has applied to move to the OTCQB. On July 19, 2019, the Company received final approval to list its common shares on the Canadian Securities Exchange (the "CSE"), and to voluntarily delist its common shares from the Exchange. The common shares commenced trading on the CSE at the market opening on July 23, 2019. The Company is focused on the development and commercialization of drugs for underserved medical needs. The Company's registered and legal office is located at The Canadian Venture Building, 82 Richmond Street East, Toronto, Ontario M5C 1P1.

These consolidated financial statements were prepared on a going concern basis of presentation, which assumes that the Company will continue operations for the foreseeable future and be able to realize the carrying value of its assets and discharge its liabilities and commitments in the normal course of business. To date, the Company has not earned revenue and has an accumulated deficit of \$16,321,048 as at June 30, 2020 (June 30, 2019 - \$10,939,361). As at June 30, 2020, the Company had cash and cash equivalents of \$1,381,483 (June 30, 2019 - \$475,234) and a working capital of \$1,786,048 (June 30, 2019 - working capital of \$206,552). The Company's ability to continue as a going concern is dependent upon its ability to obtain additional financing and or achieve profitable operations in the future. Management is aware, in making its assessment, of material uncertainties related to events or conditions that cast significant doubt upon the Company's ability to continue as a going concern. These consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. These adjustments could be material. Management is actively pursuing funding options, being financing and alternative funding options, required to meet the Company's requirements on an ongoing basis.

The Company's operations could be significantly adversely affected by the effects of a widespread global outbreak of a contagious disease, including the recent outbreak of respiratory illness caused by Novel Coronavirus ("COVID-19"). The Company cannot accurately predict the impact COVID-19 will have on its operations and the ability of others to meet their obligations with the Company, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect the Company's operations and ability to finance its operations.

These consolidated financial statements were authorized for issuance by the Board on October 21, 2020.

2. Significant Accounting Policies

Statement of compliance

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and Interpretations of the IFRS Interpretations Committee ("IFRIC"), effective for the Company's reporting for the year ended June 30, 2020.

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

2. Significant Accounting Policies (continued)

Basis of measurement

These consolidated financial statements are stated in Canadian dollars and were prepared on a historical cost basis except for certain items which may be accounted for at fair value as further discussed in the subsequent notes, using the significant accounting policies and measurement basis summarized below.

Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars which is the Company's functional and presentation currency.

Transactions in currencies other than the functional currency are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at the period end exchange rates are recognized in the consolidated statements of comprehensive loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company has power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Revive Therapeutics Inc. The financial statements of the Company's wholly owned subsidiaries, Revive Therapeutics Inc. and Psilocin Pharma Corp., are included in the consolidated financial statements from the date that control commences until the date that control ceases.

Investments in subsidiaries are carried at their cost of acquisition in the Company's financial statements. The financial statements of subsidiaries are prepared for the same reporting period as the parent entity, using consistent accounting policies.

All inter-company balances and transactions between entities in the Company, including any unrealized profits or losses, have been eliminated on consolidation.

Cash and cash equivalents

Cash and cash equivalents in the consolidated statements of financial position comprise cash at banks and with investment broker. The Company's cash is invested with major financial institutions in business accounts that are available on demand by the Company for its operations.

Financial instruments

The Company adopted IFRS 9 in its consolidated financial statements on July 1, 2018.

IFRS 9 -Financial Instruments ("IFRS 9") includes guidance on the classification, recognition and measurement, impairment, derecognition and general hedge accounting of financial assets and liabilities.

Financial assets within the scope of IFRS 9 are classified in the following measurement categories: amortized cost, fair value through profit and loss ("FVTPL") or fair value through other comprehensive income ("FVTOCI") based on the business model in which they are held and the characteristics of their contractual cash flows. Financial liabilities are classified in the following measurement categories: FVTPL, or amortized cost.

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

2. Significant Accounting Policies (continued)

Financial instruments (continued)

All financial instruments are initially recognized at fair value on the consolidated statement of financial position. Subsequent measurement of financial instruments is based on their classification. Financial assets and liabilities classified at FVTPL are measured at fair value with changes in those fair values recognized in the consolidated statement of loss and comprehensive loss for the period. Financial assets classified at amortized cost and financial liabilities are measured at amortized cost using the effective interest method.

Financial assets

All financial assets are recognized initially at fair value plus, in the case of investments not at FVTPL, directly attributable transaction costs on the trade date at which the Company becomes a party to the contractual provisions of the instruments.

Where fair values of financial assets recorded on the consolidated statement of financial position cannot be derived from active markets, they are determined using a variety of valuation techniques. The inputs to these models are derived from observable market data where possible, but where observable market data are not available, judgement is required to establish fair values.

Financial assets are classified as either financial assets at FVTPL, amortized cost, or FVTOCI. The Company determines the classification of its financial assets at initial recognition.

i. Financial assets recorded at FVTPL

Financial assets are classified as FVTPL if they do not meet the criteria of amortized cost or FVTOCI. Gains or losses on these items are recognized in profit or loss. The Company's cash and cash equivalent and investments are classified as financial asset measured at FVTPL.

ii. Amortized cost

Financial assets are classified as measured at amortized cost if both of the following criteria are met and the financial assets are not designated as at FVTPL: 1) the object of the Company's business model for these financial assets is to collect their contractual cash flows; and 2) the asset's contractual cash flows represent "solely payments of principal and interest". They are carried at amortized cost less any provision for impairment. Individually significant receivables are considered for impairment when they are past due or when other objective evidence is received that a specific counterparty will default.

The Company's lease receivable is classified as a financial asset measured at amortized cost.

iii. Financial assets recorded at FVTOCI

Financial assets are recorded at FVTOCI when the change in fair value is attributable to changes in the Company's credit risk. The Company has no financial assets classified or measured at FVTOCI.

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

2. Significant Accounting Policies (continued)

Financial instruments (continued)

Impairment of financial assets

The impairment model under IFRS 9 is applicable to financial assets measured at amortized cost where any expected future credit losses are provided for, irrespective of whether a loss event has occurred as at the reporting date. The Company's only financial assets subject to impairment are amounts received which are measured at amortized costs. The Company has elected to apply the simplified approach on impairment as permitted by IFRS 9, which requires the expected lifetime loss to be recognized at the time of initial recognition of the receivable. An impairment loss is reversed in subsequent periods if the amount of the expected loss decreases and the decrease can be objectively related to an event occurring after the initial impairment was recognized. The Company has measured the lifetime expected credit losses taking into consideration historical credit loss experience and financial factors specific to debtors and other relevant factors.

Financial liabilities

Non-derivative financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL as it is in the case for held for trading or derivative instruments, or the Company has opted to measure the financial liability at FVTPL.

All financial liabilities are recognized initially at fair value and in the case of loans and borrowings, net of directly attributable transaction costs.

Financial liabilities are classified as either financial liabilities at FVTPL or at amortized cost. The Company determines the classification of its financial liabilities at initial recognition.

i. Amortized cost

Financial liabilities are classified as measured at amortized cost unless they fall into one of the following categories: financial liabilities at FVTPL, financial liabilities that arise when a transfer of a financial asset does not qualify for derecognition, financial guarantee contracts, commitments to provide a loan at a below-market interest rate, or contingent consideration recognized by an acquirer in a business combination.

The Company's accounts payable and accrued liabilities, lease liability statute barred liabilities, convertible debenture and loan payable are classified as measured at amortized cost.

ii. Financial liabilities recorded FVTPL

Financial liabilities are classified as FVTPL if they do not fall into amortized cost detailed above.

Transaction costs

Transaction costs associated with financial instruments, carried at FVTPL, are expensed as incurred, while transaction costs associated with all other financial instruments are included in the initial carrying amount of the asset or the liability.

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

2. Significant Accounting Policies (continued)

Financial instruments (continued)

Subsequent measurement

Instruments classified as FVTPL are measured at fair value with unrealized gains and losses recognized in the consolidated statement of loss and comprehensive loss. Instruments classified as amortized cost are measured at amortized cost using the effective interest rate method. Instruments classified as FVTOCI are measured at fair value with unrealized gains and losses recognized in other comprehensive income.

Derecognition

Financial assets – The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset have expired or when contractual rights to the cashflows have been transferred. Gains and losses from the derecognition are recognized in the statements of loss and comprehensive loss.

Financial liabilities – The Company derecognizes a financial liability when the obligation specified in the contract is discharged, canceled or expired. The difference between the carrying amount of the derecognized financial liability and the consideration paid or payable, including noncash assets transferred, or liabilities assumed, is recognized in the statements of loss and comprehensive loss.

Privately-held investments

All privately-held investments (other than options and warrants) are initially recorded at the transaction price, being the fair value at the time of acquisition. Thereafter, at each reporting period, the fair value of an investment may (depending upon the circumstances) be adjusted using one or more of the valuation indicators described below. These are included in Level 3 in Note 4. Options and warrants of private companies are valued using an option pricing model when there are sufficient and reliable observable market inputs; if no such market inputs are available, the warrants and options are valued using alternative methods representing fair value.

The determinations of fair value of the Company's privately-held investments are subject to certain limitations. Financial information for private companies in which the Company has investments may not be available and, even if available, that information may be limited and/or unreliable.

Use of the valuation approach described below may involve uncertainties and determinations based on the Company's judgment and any value estimated from these techniques may not be realized or realizable.

Company-specific information is considered when determining whether the fair value of a privately-held investment should be adjusted upward or downward at the end of each reporting period. In addition to company-specific information, the Company will take into account trends in general market conditions and the share performance of comparable publicly-traded companies when valuing privately-held investments.

The absence of the occurrence of any of these events, any significant change in trends in general market conditions, or any significant change in share performance of comparable publicly-traded companies may indicate generally that the fair value of the investment has not materially changed. The fair value of a privately-held investment requires adjustment if:

- a. there has been a significant subsequent equity financing provided by outside investors at a valuation different than the current value of the investee company, in which case the fair value of the investment is set to the value at which that financing took place;

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements For the Years Ended June 30, 2020 and 2019 (Expressed in Canadian dollars)

2. Significant Accounting Policies (continued)

Privately-held investments (continued)

b. there have been significant corporate, political or operating events affecting the investee company that, in management's opinion, have a material impact on the investee company's prospects and therefore its fair value. In these circumstances, the adjustment to the fair value of the investment will be based on management's judgment and any value estimated may not be realized or realizable;

c. the investee company is placed into receivership or bankruptcy;

d. based on financial information received from the investee company, it is apparent to the Company that the investee company is unlikely to be able to continue as a going concern; and

e. important positive/negative management changes by the investee company that the Company's management believes will have a very positive/negative impact on the investee company's ability to achieve its objectives and build value for shareholders.

Adjustments to the fair value of a privately-held investment will be based upon management's judgment and any value estimated may not be realized or realizable. The resulting values for non-publicly traded investments may differ from values that would be realized if a ready market existed.

Equipment and intangible assets

Equipment and intangible assets are carried at cost, less accumulated depreciation and amortization and accumulated impairment losses.

The cost of an item of equipment and intangible assets consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use, borrowing costs directly associated with the item and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located.

Depreciation and amortization are recognized based on the cost of an item of equipment and intangible assets, less its estimated residual value, over its estimated useful life at the following rates:

<u>Detail</u>	<u>Rate</u>	<u>Method</u>
Equipment	20% - 30%	Declining balance
Intangible assets	5 - 20 years	Straight-line

The Company does not start amortization for intangible assets with patent pending as they are not available for use.

An asset's residual value, useful life and depreciation method are reviewed, and adjusted if appropriate, on an annual basis.

An item of equipment and intangible assets is de-recognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in profit or loss in the statements of comprehensive loss.

Where an item of equipment and intangible assets consists of major components with different useful lives, the components are accounted for as separate items of equipment and intangible assets. Expenditures incurred to replace a component of an item of equipment and intangible assets that is accounted for separately, including major inspection and overhaul expenditures, are capitalized.

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

2. Significant Accounting Policies (continued)

Research and development

Expenditures during the research phase are expensed as incurred. Expenditures during the development phase are capitalized as internally generated intangible assets if the Company can demonstrate each of the following criteria:

- the technical feasibility of completing the intangible asset so that it will be available for use or sale;
- its intention to complete the intangible assets and use or sell it;
- how the asset will generate future economic benefits;
- the availability of resources to complete the asset; and
- the ability to measure reliably the expenditure during development.

Impairment of non-financial assets

Non-financial assets are reviewed for impairment if there is any indication that the carrying amount may not be recoverable. If any such indication is present, the recoverable amount of the asset is estimated in order to determine whether impairment exists. Where the asset does not generate cash flows that are independent from other assets, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs. Any intangible asset with an indefinite useful life is tested for impairment annually and whenever there is an indication that the asset may be impaired. Finite life intangible assets not yet available for use are tested annually for impairment.

An asset's recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value, using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset or cash generating unit is estimated to be less than its carrying amount, the carrying amount is reduced to the recoverable amount. An impairment loss is recognized immediately in profit or loss. Where an impairment subsequently reverses, the carrying amount is increased to the revised estimate of recoverable amount, but only to the extent that this does not exceed the carrying value that would have been determined if no impairment had previously been recognized. A reversal is recognized in profit or loss for the period.

Provisions

A provision is recognized in the statements of financial position when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and the amount can be reliably estimated. If the effect is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability.

A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract.

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

2. Significant Accounting Policies (continued)

Stock-based compensation

The fair value of stock options granted to employees is recognized as an expense with a corresponding increase in equity. An individual is classified as an employee when the individual is an employee for legal or tax purposes (direct employee) or provides services similar to those performed by a direct employee, including directors of the Company. The fair value is measured at the grant date and recognized over the period during which the options vest. The fair value of the options granted is measured using the Black-Scholes option pricing model taking into account the terms and conditions upon which the options were granted. At the end of each reporting period, the amount recognized as an expense is adjusted to reflect the actual number of share options that are expected to vest.

Warrant reserve

The fair value of warrants is determined upon their issuance either as part of unit private placements or in settlement of share issuance costs and finder's fees, using the Black-Scholes model. All such warrants are classified in a warrant reserve within equity. If the warrants are converted, the value attributable to the warrants is transferred to common share capital. Upon expiry, the amounts recorded for expired warrants is transferred to equity from the warrant reserve. Shares are issued from treasury upon the exercise of share purchase warrants.

Income taxes

Income tax expense consists of current and deferred tax expenses. Current and deferred tax are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or other comprehensive income.

Current tax is recognized and measured at the amount expected to be recovered from or payment to the taxation authorities based on the income tax rates enacted or substantively enacted at the end of the reporting period and includes any adjustment to taxes payable in respect of previous years.

Deferred tax is recognized on any temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable earnings. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized and the liability is settled. The effect of a change in the enacted or substantively enacted tax rates is recognized in net earnings and comprehensive income or in equity depending on the item to which the adjustment relates.

Deferred tax assets are recognized to the extent future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable that sufficient taxable earnings will be available to allow all or part of the assets to be recovered.

Loss per share

The Company presents basic and diluted loss per share data for its common shares, calculated by dividing the loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined by adjusting the loss attributable to common shareholders and the weighted average number of common shares outstanding for the effects of all dilutive potential common shares.

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

2. Significant Accounting Policies (continued)

Significant accounting judgments and estimates

The application of the Company's accounting policies in compliance with IFRS requires the Company's management to make certain judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. These estimates and assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the financial position reporting date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

- i. the recoverability and useful lives of capitalized intangible assets and equipment which are included in the consolidated statements of financial position. Management's assessment of whether indicators of impairment are present requires judgment based on facts and circumstances at reporting period ends.
- ii. The Company measures the cost of stock-based payment transactions with employees and directors by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for stock-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining and making assumptions about the most appropriate inputs to the valuation model including the expected life, volatility, dividend yield of the share option and forfeiture rate.
- iii. Estimating fair value for warrants and broker and finder warrants requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining and making assumptions about the most appropriate inputs to the valuation model including the expected life, volatility, dividend yield of the share option and forfeiture rate.
- iv. Management decision that no provision is needed for the contingency in note 23 represents management estimates and the eventual resolution of the liability may differ based on additional information and the occurrence of future events.
- v. Fair value of investment. The fair value of investment recorded on the consolidated statements of financial position cannot be derived from active markets and is determined using a valuation model, the inputs to which are derived from observable market data where possible, but where observable market data are not available, judgment is required to establish the fair value. Refer to note 4 for details.
- vi. These consolidated financial statements have been prepared in accordance with IFRS on a going concern basis, which assumes the realization of assets and discharge of liabilities in the normal course of business within the foreseeable future. Management uses judgment in determining assumptions for cash flow projections, such as anticipated financing, anticipated sales and future commitments to assess the Company's ability to continue as a going concern. A critical judgment is that the Company continues to raise funds going forward and satisfy their obligations as they become due.

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

2. Significant Accounting Policies (continued)

Share capital

Common shares are classified as equity. Incremental costs directly attributable to the issue of new shares or warrants are shown in equity as a deduction, net of tax, from the proceeds.

Compound instruments - convertible debenture

The components of compound instruments issued by the Company are classified separately as financial liabilities and equity in accordance with the contractual agreement. At the date of issue, the fair value of the liability component is estimated using the market interest rate then in effect for a similar non-convertible instrument. This amount is recorded as a liability, at amortized cost, using the effective interest rate method until its expiry at the time of conversion or maturity of the instrument. The equity component is determined by deducting the amount of the liability component of the total fair value of the compound instrument. This amount is recognized in equity, net of income tax effects, and is not subsequently remeasured.

Transaction costs related to the issuance of the convertible debenture are allocated to the liability and equity components in proportion to their initial carrying amounts. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortized over the life of the debenture using the effective interest method. Interest and accretion expense are recognized as a finance cost in the consolidated statements of comprehensive loss.

Adoption of new accounting policy

Lessee

In January 2016, the IASB issued IFRS 16 - Leases ("IFRS 16"), replacing IAS 17 - Leases. IFRS 16 provides a single lessee accounting model and requires the lessee to recognize assets and liabilities for all leases on its statement of financial position, providing the reader with greater transparency of an entity's lease obligations. The Company adopted IFRS 16 – Leases on July 1, 2019. Previously, the Company classified leases as operating or finance leases based on IAS 17 - Leases.

The Company adopted IFRS 16 under the modified retrospective approach. Comparatives for 2019 were not restated. At transition, the Company elected to use the practical expedient available under the standard that allows lease assessments made under IAS 17 and IFRIC 4 to be used for existing contracts. Therefore, the definition of a lease under IFRS 16 was applied only to contracts entered into or changed on or after July 1, 2019. The Company has determined that there is no change to the comparative periods required as a result of the adoption of this standard.

On initial application, for leases previously classified as operating leases under IAS 17, the Company has elected to record right-of-use assets based on the corresponding lease liability. On July 1, 2019, the adoption of IFRS 16 had no material impact on the Company's consolidated financial statements with the Company's existing lease agreement which expired on August 31, 2019. On September 1, 2019, the Company entered into a new lease agreement for which the Company recorded lease obligations of \$474,474 and right-of-use assets of \$486,890, with no net impact on deficit (See Notes 10 and 13).

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

2. Significant Accounting Policies (continued)

Adoption of new accounting policy (continued)

Lessee (continued)

When measuring lease liabilities for those leases previously classified as operating leases under IAS 17, the Company discounted future lease payments using its incremental borrowing rate as at September 1, 2019. The weighted-average rate applied is 20%.

The Company has elected to apply the practical expedient on facility leases, not to separate non-lease components from lease components, and instead account for each lease component and any associated non-lease components as a single lease component.

The Company's accounting policy for leases under IFRS 16 is as follows:

At inception of a contract, the Company assesses whether a contract is, or contains, a lease. Contracts that convey the right to control the use of an identified asset for a period of time in exchange for consideration are accounted for as leases giving rise to right-of-use assets.

At the commencement date, a right-of-use asset is measured at cost, where cost comprises: (a) the amount of the initial measurement of the lease liability; (b) any lease payments made at or before the commencement date, less any lease incentives received; (c) any initial direct costs incurred by the Company; and (d) an estimate of costs to be incurred by the Company in dismantling and removing the underlying asset, restoring the site on which it is located or restoring the underlying asset to the condition required by the terms and conditions of the lease.

Significant accounting judgments, estimates and assumptions in adoption of IFRS 16

A lease liability is initially measured at the present value of the unpaid lease payments discounted using the interest rate implicit in the lease or if that rate cannot be reliably determined, the Company's incremental borrowing rate. Subsequently, the Company measures a lease liability at amortized cost using the effective interest method. It is then remeasured to reflect revised in-substance fixed lease payments. Except where the costs are included in the carrying amount of another asset, the Company recognizes in profit or loss (a) the interest on a lease liability and (b) variable lease payments not included in the measurement of a lease liability in the period in which the event or condition that triggers those payments occurs. The Company subsequently measures a right-of-use asset at cost less any accumulated depreciation and any accumulated impairment losses; and adjusted for any re-measurement of the lease liability. Right-of-use assets are depreciated over the shorter of the asset's useful life and the lease term.

All the components of the lease liability are required to be discounted to reflect the present value of the payments. The discount rate to use is the rate implicit in the lease, unless this cannot readily be determined, in which case the lessee's incremental borrowing rate is used instead. The definition of the lessee's incremental borrowing rate states that the rate should represent what the lessee would have to pay to borrow over a similar term and with similar security, the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. Significant judgment is required to estimate an incremental borrowing rate in the context of a right-of-use asset.

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

2. Significant Accounting Policies (continued)

Adoption of new accounting policy (continued)

Sub-lease

When the Company is an intermediate lessor, it determines at lease inception date whether the sub-lease is a finance lease or an operating lease based on whether the contract transfers substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case, then the sub-lease is a finance lease; if not, then it is an operating lease. Payments from sub-leases that are determined to be operating leases are recorded as cost recovery under general and administrative expenses in the period the payment is due.

For finance leases, and when the Company acts as intermediate lessor, it recognizes a sublease receivable and derecognizes the right-of-use assets relating to the head lease that it transfers to the sub lessees. Right-of-use assets and lease receivables relating to the sub leases are measured in the same way as the right-of-use assets and lease liabilities for the head lease, using the same discount rate to measure the present value of the future payments to be received.

The Company presents accretion expense in the head lease separate from the accretion income from the sub-lease.

On December 11, 2019, the Company sub-leased the right-of-use asset that the Company leased on September 1, 2019 and recognized a loss on sub-lease of \$9,038.

Uncertainty over Income Tax Treatments

In June 2017, the IASB issued IFRIC 23 Uncertainty over Income Tax Treatments with a mandatory effective date of January 1, 2019. The interpretations provide guidance on how to value uncertain income tax positions based on the probability of whether the relevant tax authorities will accept a Corporation's tax treatments. A Corporation is to assume that a taxation authority, with the right to examine any amounts reported to it, will examine those amounts and will have full knowledge of all relevant information when doing so. IFRIC 23 is to be applied by recognizing the cumulative effect of initially applying these guidelines in opening retained earnings without adjusting comparative information. For the period beginning July 1, 2019, the implementation of IFRIC 23 did not have a material effect on the consolidated financial statements.

New interpretations issued but not yet effective

(a) IFRS 3. In October 2018, the IASB issued amendments to IFRS 3 "Definition of a Business" The amendments clarify the definition of a business, with the objective of assisting entities to determine whether a transaction should be accounted for as a business combination or as an asset acquisition. The amendment provides an assessment framework to determine when a series of integrated activities is not a business. The amendments are effective for business combinations occurring on or after the beginning of the first annual reporting period beginning on or after January 1, 2020. The Company will adopt these standards effective July 1, 2020 and does not believe this new standard will have a material impact on these financial statements.

(b) IAS 1 "Presentation of Financial Statements" and IAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors" were amended in October 2018 to refine the definition of materiality and clarify its characteristics. The revised definition focuses on the idea that information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements. The amendments are effective for annual reporting periods beginning on or after January 1, 2020. The Company will adopt these standards effective July 1, 2020 and does not believe this new standard will have a material impact on these financial statements.

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

3. Capital Management

The Company manages its capital with the following objectives:

- to ensure sufficient financial flexibility to achieve the ongoing business objectives including funding of future growth opportunities, and pursuit of accretive acquisitions; and
- to maximize shareholder return through enhancing the share value.

The Company monitors its capital structure and makes adjustments according to market conditions in an effort to meet its objectives given the current outlook of the business and industry in general. The Company may manage its capital structure by issuing new shares, repurchasing outstanding shares, adjusting capital spending, or disposing of assets. The capital structure is reviewed by management and the Board of Directors on an ongoing basis. The Company considers its capital to be equity comprising share capital, warrants, broker and finder warrants, contributed surplus and accumulated deficit which at June 30, 2020 totalled \$7,429,029 (June 30, 2018 - \$960,782). The Company manages capital through its financial and operational forecasting processes. The Company reviews its working capital and forecasts its future cash flows based on operating expenditures, and other investing and financing activities. Selected information is provided to the Board of Directors of the Corporation. The Company's capital management objectives, policies and processes have remained unchanged during the year ended June 30, 2020.

4. Financial Risk Factors

The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk and market risk (including interest rate and foreign currency risk).

Risk management is carried out by the Company's management team with guidance from the Board of Directors. The Board of Directors also provides regular guidance for overall risk management.

There were no changes to the Company's objectives, policies and procedures for managing risks during the year.

Credit risk

Credit risk is the risk of loss associated with a counterparty's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash. Cash is held with select major Canadian chartered banks, from which management believes the risk of loss to be minimal.

Liquidity risk

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if the Company's access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or related to matters specific to the Company. The Company generates cash flow primarily from its financing activities. As at June 30, 2020, the Company had a cash and cash equivalents balance of \$1,381,483 (June 30, 2019 - \$475,234) to settle current liabilities of \$372,200 (June 30, 2019 - \$321,772) (note 11). The Company regularly evaluates its cash position to ensure preservation and security of capital as well as maintenance of liquidity.

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

4. Financial Risk Factors (continued)

Market risk

(a) Interest rate risk

The Company has cash balances. The Company's current policy is to invest excess cash held as collateral in guaranteed investment certificates or interest bearing accounts of select major Canadian chartered banks. The Company regularly monitors its cash activities in compliance with its cash management policy.

The Company is exposed to the risk that the value of financial instruments will change due to movements in market interest rates. As of June 30, 2020, the Company's interest rate risk mainly relates to cash balances. Sensitivity to a plus or minus 1% change in interest rates would affect the reported comprehensive loss by approximately \$14,000 (June 30, 2019 - \$4,700).

(b) Foreign currency risk

The Company's functional and reporting currency is the Canadian dollar. As of June 30, 2020, sensitivity to a plus or minus 10% change in US dollar foreign exchange rate would affect the reported comprehensive loss by approximately \$19,000 (June 30, 2019 - \$9,400).

5. Fair Value Measurements

The following table illustrates the classification of the Company's financial instruments recorded at fair value within the fair value hierarchy as at June 30, 2020 and June 30, 2019:

June 30, 2020	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$ 1,381,483	\$ -	\$ -	\$ 1,381,483
Investment	100,000	-	250,000	350,000
June 30, 2019	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$ 475,234	\$ -	\$ -	\$ 475,234
Investment	-	-	750,000	750,000

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

5. Fair Value Measurements (continued)

Level 3 hierarchy:

The following table presents the changes in fair value measurement of financial instrument classified as Level 3. The financial instrument is measured at fair value utilizing non-observable market inputs.

Investment at fair value	Opening balance at July 1, 2019	Unrealized loss	Ending balance at June 30, 2020
June 30, 2020	\$ 750,000	\$ (500,000)	\$ 250,000

Within Level 3, the Company includes a non-public company investment. The key assumptions used in the valuation of the instrument include (but are not limited to) the value at which a recent financing was done by the investee.

The following table presents the fair value, categorized by key valuation techniques and the unobservable inputs used within Level 3 as at:

June 30, 2020

Investment name	Valuation technique	Fair value	Unobservable inputs
Herman Holdings Limited ("HHL")	recent financing	\$ 250,000	Transaction price

As the valuation of investments for which market quotations are not readily available and are inherently uncertain, the values may fluctuate materially within short periods of time and are based on estimates, and determinations of fair value may differ materially from values that would have resulted if a ready market existed for the investments. As at June 30, 2020, a change in the transaction price of 5% would result in an increase/decrease in the fair value estimate of the investment of approximately \$12,500, keeping all other variables constant.

6. Lease receivable

Balance, July 1, 2019	\$ -
Additions	450,628
Reduction of lease receivable in settlement of lease liability and others	(72,319)
Finance income	47,595
Balance, June 30, 2020	\$ 425,904

Allocated as:

Current	\$ 76,763
Long-term	349,141
	\$ 425,904

The underlying sub-lease agreement terminates on August 31, 2024.

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

7. Investments

Privately-held investment

In connection with the closing of the non-brokered private placement in February 2019, Revive acquired an aggregate of 2,500,000 common shares of HHL at a price of \$0.30 per common share of HHL for gross payment of \$750,000 representing 5% of the issued and outstanding HHL Shares. During the year ended June 30, 2020, the Company recorded an unrealized loss of \$500,000 on investment in HHL common shares and as at June 30, 2020, the fair value of the investment was recorded at \$250,000.

Investment in a public company

On February 10, 2020, the Company entered into a supply and collaboration agreement (the "Agreement") with Red Light Holland Financing Inc. ("Red Light"), an arm's length party. Pursuant to the Agreement Red Light will sell to Revive a consistent strain of truffles for the sole purpose of Revive undertaking research and development on the suitability and implementation of its novel cannabinoid delivery technology with respect to the truffles and its extracts. Red Light has also agreed to, upon request, provide Revive with any information, studies, papers and other information it may have pertaining to the truffles which may be deemed to be beneficial to Revive for undertaking the research and development. Revive issued to Red Light an aggregate of 3,000,000 common shares valued at \$195,000 based on Revive's stock price on the date of issuance in consideration of 2,500,000 Red Light shares. During the year ended June 30, 2020, the Company sold 1,250,000 Red Light shares for proceeds of \$142,240 in the Company investment broker's account which were included in cash and cash equivalents on the consolidated statement of financial position as at June 30, 2020. The disposition of Red Light shares resulted in a gain on disposition of investment of \$44,740.

8. Intangible Assets

Cost	REV-002	Psilocin	Total
Balance, June 30, 2018	\$ 35,876	\$ -	\$ -
Additions	685	-	685
Write-off	(36,561)	-	(36,561)
Balance, June 30, 2019	-	-	-
Additions	-	5,500,000	5,500,000
Balance, June 30, 2020	\$ -	\$ 5,500,000	\$ 5,500,000

Accumulated amortization	REV-002	Psilocin	Total
Balance, June 30, 2018	\$ 7,378	\$ -	\$ 7,378
Amortization during the year	1,798	-	1,798
Write-off	(9,176)	-	(9,176)
Balance, June 30, 2019 and 2020	-	-	-

Carrying value	REV-002	Psilocin	Total
Balance, June 30, 2019	\$ -	\$ -	\$ -
Balance, June 30, 2020	\$ -	\$ 5,500,000	\$ 5,500,000

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

8. Intangible Assets (continued)

Psilocin

On March 5, 2020, the Company completed its acquisition of all of the issued and outstanding securities in the capital of Psilocin Pharma Corp. ("Psilocin"), an arm's length party incorporated pursuant to the laws of the Province of Ontario. Psilocin is a specialty psychedelic sciences company focused on the development of Psilocybin-based therapeutics for significant unmet medical needs including rare and orphan indications.

Pursuant to the terms of a share exchange agreement dated March 4, 2020, Revive acquired all of the issued and outstanding securities of Psilocin through the issuance of an aggregate of 55 million common shares in the capital of Revive.

Psilocin was determined not to meet the definition of a business as per IFRS 3 as substantially all of the fair value of Psilocin was concentrated in one asset: its intellectual property. Accordingly, the acquisition was treated as an asset acquisition.

Details of the allocation of the estimated fair value of identifiable assets acquired and purchase consideration are as follows:

Purchase consideration:	5,500,000
--------------------------------	-----------

Identifiable net assets acquired:	
Intellectual property	5,500,000

Psilocin has developed patent-pending formulation and production solutions for the active compound Psilocybin. The process encompassed with its intellectual property cover methods of production of Psilocybin-based formulations. Psilocin has developed formulations to date which include the Hydroxy Line. The line will include PSY-0.1 -Capsules, PSY-0.2 -Sublingual Spray, PSY-0.3 -Gel Cap, PSY-0.4/0.5 -Effervescent Tablets, and PSY-0.6 -Breath Strips. The precisely dosed formulations will work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to U.S. Food and Drug Administration ("FDA") approval in the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and a number of other diseases. Psilocin's range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption.

Psilocin has filed key provisional patent applications with the U.S. Patent and Trademark Office that cover methods of production of Psilocybin-based formulations. Furthermore, Psilocin has a patent-pending portfolio that includes Psilocybin extraction and crystallization methodologies.

The costs of provisional patents and pending applications are not amortized until the patent is approved and are reviewed each reporting period to determine if it is likely that the patent will be successfully granted.

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

8. Intangible Assets (continued)

REV-002

On June 17, 2013, Revive and Xenexus Pharmaceuticals Pty Ltd. ("Xenexus") entered into a patent assignment agreement (the "REV-002 Agreement"), which replaced and superseded a patent license agreement (the "REV-002 License") between Revive and Xenexus dated April 3, 2013. The REV-002 Agreement and its predecessor grant Revive the right to commercially exploit U.S. patent No. 9238018, titled 'The Use of Bucillamine in the Treatment of Gout' which was then subsequently replaced by U.S. patent No. 9662305. Pursuant to the REV-002 License, the Company was required to pay an initial annual license fees amounting to \$10,000. Between April 3, 2013, and June 17, 2013, the Company paid \$10,000 in accordance with the REV-002 License. Pursuant to the REV-002 Agreement, the Company acquired Patent Document AU2012905072, which was replaced by U.S. patent No. 9238018, titled 'The Use of Bucillamine in the Treatment of Gout' which was then subsequently replaced by U.S. patent No. 9662305, in exchange for a \$15,000 cash payment (paid). If the Company licenses the patent acquired under the REV-002 Agreement, it will be required to pay to Xenexus 5% of any upfront milestone payments and subsequent milestone fees from its licensee. To date, no milestone payments have been incurred or paid. As of June 30, 2018, the Company was in compliance with the terms of the REV-002 Agreement.

On January 29, 2015, the Company announced the initiation of a Phase II – A clinical study in patients with gout in the U.S.

On December 1, 2015, the Company announced final results from its Phase II-A clinical study in patients with gout in the U.S.

On February 26, 2015, Revive announced the expansion of its orphan drug indication pipeline to include the drug Bucillamine for the treatment of cystinuria and Wilson disease for which the Company expects to conduct US-based clinical trials. The addition of cystinuria and Wilson disease was the result of the Company amending the material transfer agreement (the "MTA"), announced on February 20, 2014, with its global pharmaceutical partner headquartered in Osaka, Japan.

Pursuant to the amended MTA, Revive will obtain access to confidential information and clinical trial supply of the drug Bucillamine for cystinuria and Wilson disease, which the Company expects to conduct US-based clinical trials. The Company will continue to have access to confidential information and clinical trial supply of the drug Bucillamine for the treatment of gout. In return, the global pharmaceutical company will have exclusive commercialization rights in Japan, Korea and Taiwan, and Revive will have exclusive commercialization rights in the rest of the world.

As of June 30, 2019, the Company wrote off the intangible asset under REV-002 as the Company has no further plan to commercially exploit the patent.

During the year ended June 30, 2020, the Company incurred \$21,627 (2019 - \$27,900) in REV-002 research costs for consulting services of clinical trial design and research.

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

8. Intangible Assets (continued)

REV-004 and REV-005

During the year ended June 30, 2020, the Company incurred \$8,153 (2019 - \$4,898) research costs for REV - 004 and \$nil (2019 - \$nil) research costs for REV-005.

CANNABINOIDS

During the year ended June 30, 2020, the Company incurred \$6,653 (2019 - \$86,218) research costs for cannabinoids.

BUCILLAMINE

Bucillamine is a disease-modifying anti-rheumatic drug, which is prescribed for rheumatoid arthritis in Japan and South Korea. The Company pursued the repurposing of bucillamine as a potential new treatment for gout and cystinuria. The Company entered into a material transfer agreement (“MTA”) with the developer of bucillamine. The Company is exploring the use of Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (COVID-19).

During the year ended June 30, 2020, the Company incurred \$304,742 (2019 - \$nil) research costs for Bucillamine.

PSILOCYBIN

With the acquisition of Psilocin Pharma Corp. (“Psilocin”), the Company is exploring novel psilocybin-based formulations.

During the year ended June 30, 2020, the Company incurred \$42,827 (2019 - \$nil) research costs for Psilocybin-based formulations.

DRUG DELIVERY TECHNOLOGY

The Company is focused on commercializing novel delivery technologies to effectively deliver psychedelics and cannabinoids through the skin and/or directly into the affected area of the skin, otherwise known as topical delivery and also via the mouth, otherwise known as buccal delivery.

During the year ended June 30, 2020, the Company incurred \$70,695 (2019 - \$nil) research costs for drug delivery technology.

OTHER

During the year ended June 30, 2020, the Company incurred \$392 (2019 - \$5,793) general research costs not specifically allocated to any particular project.

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

9. Equipment

Cost	Computer Equipment	Office Equipment	Total
Balance, June 30, 2018, 2019 and 2020	\$ 7,171	\$ 7,737	\$ 14,908
Accumulated depreciation	Computer Equipment	Office Equipment	Total
Balance, June 30, 2018	\$ 4,393	\$ 4,882	\$ 9,275
Depreciation during the year	833	570	1,403
Balance, June 30, 2019	\$ 5,226	\$ 5,452	\$ 10,678
Depreciation during the year	583	456	1,039
Balance, June 30, 2020	\$ 5,809	\$ 5,908	\$ 11,717
Carrying value	Computer Equipment	Office Equipment	Total
Balance, June 30, 2019	\$ 1,945	\$ 2,285	\$ 4,230
Balance, June 30, 2020	\$ 1,362	\$ 1,829	\$ 3,191

10. Right-of-use Asset

	Manufacturing facility
Balance, July 1, 2019	\$ -
Addition	486,890
Amortization	(27,224)
Transferred to sub-lease receivable	(459,666)
Balance, June 30, 2020	\$ -

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

11. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities of the Company are principally comprised of amounts outstanding for purchases relating to research and development and general operating activities.

	As at June 30, 2020	As at June 30, 2019
Accounts payable	\$ 210,025	\$ 199,641
Accrued liabilities	92,161	122,044
HST payable	-	87
	\$ 302,186	\$ 321,772

	As at June 30, 2020	As at June 30, 2019
Less than 1 month	\$ 244,829	\$ 210,027
1 to 3 months	6,630	52
Greater than 3 months	50,727	111,693
	\$ 302,186	\$ 321,772

12. Statute Barred Liabilities

During the year ended June 30, 2020, the Company transferred \$63,511 of accounts payable (the "Statute-barred Claims") to non-current liabilities on the basis that any claims in respect of the Statute-barred Claims were statute barred under the Limitations Act (Ontario). The Statute-barred Claims relate to expenses billed by third-party vendors. Under IFRS, a financial liability can only be derecognized from the Company's Statement of Financial Position when it is extinguished, meaning only when the contract is discharged or canceled or expires. The effect of the Limitations Act is to prevent a creditor from enforcing an obligation, but it does not formally extinguish the financial liability under IFRS.

It is the position of management of the Company that the Statute-barred Claims cannot be enforced by the creditors, do not create any obligation for the Company to pay out any cash and do not affect the financial or working capital position of the Company. The Statute-barred Claims are required to be reflected on the Company's Statement of Financial Position as a result of the current interpretation of IFRS, but they are classified as non-current liabilities as the Company has no intention to pay these Statute-barred Claims and the creditors cannot enforce payment of the Statute-barred Claims.

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements For the Years Ended June 30, 2020 and 2019 (Expressed in Canadian dollars)

13. Lease Liability

Balance, July 1, 2019	\$	-
Additions		474,474
Accretion		75,543
Lease payments and settlement of lease receivable		(124,163)
Balance, June 30, 2020	\$	425,854
<hr/>		
Allocated as:		
Current	\$	70,014
Long-term		355,840
	\$	425,854

The underlying lease agreement terminates on August 31, 2024.

14. Convertible Debenture

On February 5, 2020, the Company issued 210,000 secured convertible debenture units (the "Debenture Units") to arm's length parties for aggregate gross proceeds of \$210,000. Each Debenture Unit consists of one (1) 12% secured convertible debenture (the "Convertible Debentures") maturing three (3) years from the date of issuance and 20 common share purchase warrants of Revive (the "Warrants"). Each Warrant shall entitle the holder thereof to purchase one common share in the capital of Revive (each, a "Common Share") at an exercise price of \$0.07 at any time up to February 5, 2025. The fair value of the Warrants was estimated to be \$25,348 using a valuation model incorporating Black-Scholes on the following assumptions: dividend yield of 0%; volatility of 136.52%; risk-free interest rate of 1.48%; and expected life of 5 years.

The Convertible Debentures have a maturity of 36 months from the date of issuance (the "Maturity Date") and shall bear interest at a rate of 12% per annum from the date of issue. Interest will accrue and be payable on the Maturity Date. The holder of the Convertible Debentures shall have the right to demand immediate payment of the Convertible Debentures, together with all accrued interest thereon, provided that such demand cannot be made prior to June 6, 2020.

The principal amount of each Convertible Debenture shall be convertible, for no additional consideration, into Common Shares at the option of the holder at any time prior to the close of business on the Maturity Date at a conversion price equal to \$0.05 (the "Conversion Price") per Common Share.

The Company incurred \$4,200 transaction costs for the issuance of the convertible debenture. The net proceeds of \$205,800 of the convertible debenture were separated into liability component of \$145,490, equity component of \$34,962 and warrants of \$25,348, using the effective interest rate method with an effective interest rate of 20% per annum. On June 11, 2020, the convertible debenture and accrued interest were converted to 4,368,000 common shares of the Company valued at \$1,351,700 based on the stock price of Revive on the date of issuance of the common shares. The conversion resulted in a loss on conversion of convertible debenture of \$1,194,097 based on the carrying value of the convertible debenture of \$151,518 and accrued interest of \$6,084 as at the date of conversion. During the year ended June 30, 2020, the Company recorded accretion expense of \$6,029 and interest expense of \$6,084 in the consolidated statements of comprehensive loss.

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements For the Years Ended June 30, 2020 and 2019 (Expressed in Canadian dollars)

15. Loan Payable

During the year ended June 30, 2020, the Company applied for the COVID-19 Relief Line of Credit as part of the Government-sponsored Canada Emergency Business Account (CEBA). The credit limit of \$40,000 has an interest rate of 0% until December 31, 2020. On January 1, 2021, the operating line of credit will be converted to a 2-year 0% interest term loan, to be repaid by December 31, 2022 of which \$10,000 of the loan will be forgiven if \$30,000 is repaid in full on or before December 31, 2022. If on December 31, 2022 the loan is not repaid, the Company can exercise the option for a 3- year term extension at an interest rate of 5% on the balance over the term extension period. The Company expects to pay the loan prior to December 31, 2022.

16. Share Capital

a) Authorized share capital

The authorized share capital consists of an unlimited number of common shares. The common shares do not have a par value. All issued shares are fully paid.

b) Common shares issued

As at June 30, 2020, the issued share capital amounted to \$19,126,095 and there were nil shares held in escrow. Changes in issued share capital are as follows:

	Number of Common Shares	Amount
Balance, June 30, 2018	58,351,282	\$ 8,423,540
Common shares issued in private placement (i)(ii)	14,010,000	1,401,000
Valuation of warrants issued in private placement (i)(ii)	-	(444,452)
Valuation of finder warrants issued in private placement (i)	-	(1,954)
Transaction costs in private placement (i)(ii)	-	(34,643)
Common shares issued for exercise of warrants	50,000	9,000
Balance, June 30, 2019	72,411,282	\$ 9,352,491
Common shares issued in private placement (iii)(v)	49,935,000	2,496,750
Valuation of warrants issued in private placement (iii)(v)	-	(956,502)
Valuation of finder warrants issued in private placement (iii)(v)	-	(280,068)
Transaction costs in private placement (iii)(v)	-	(167,725)
Common shares issued in settlement of debt (vi)	9,062,495	453,550
Common shares issued for conversion of convertible debenture (note 14)	4,368,000	1,386,662
Common shares issued for intangible asset (note 8)	55,000,000	5,500,000
Common shares issued for investment (iv)	3,000,000	195,000
Common shares issued for exercise of warrants	5,220,734	943,262
Common shares issued for exercise of broker warrants	42,000	8,254
Common shares issued for exercise of stock options	850,000	194,421
Balance, June 30, 2020	199,889,511	\$ 19,126,095

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements For the Years Ended June 30, 2020 and 2019 (Expressed in Canadian dollars)

16. Share Capital (continued)

b) Common shares issued (continued)

(i) On February 4, 2019, the Company completed the first tranche of the non-brokered private placement previously announced in the December 7, 2018 and January 23, 2019 news releases for a total of 10,960,000 units ("Units"), at a price of \$0.10 per Unit for gross proceeds of \$1,096,000 (the "Offering").

Each Unit consisted of one common share of Revive (a "Common Share") and one whole Common Share purchase warrant (each warrant, a "Warrant"). Each Warrant entitles the holder to acquire one Common Share for \$0.15 per Common Share for 24 months following closing of the Offering. Eligible finders were paid a cash fee of 6% of the gross proceeds from the Units sold with their assistance and were issued Warrants equal to 6% of the number of Units sold with their assistance. The fair value of the Warrants was estimated to be \$347,980 using a valuation model incorporating Black-Scholes on the following assumptions: dividend yield of 0%; volatility of 107.92%; risk-free interest rate of 1.84%; and expected life of 2 years. The Company incurred total transaction costs of \$37,189 including \$4,200 cash fee to finders. The Company also issued 42,000 finders' warrants with each finder's warrant exercisable into one Common Share for \$0.15 per Common Share for 24 months following closing of the Offering. The fair value of the finders' warrants was estimated to be \$1,954 using a valuation model incorporating Black-Scholes on the following assumptions: dividend yield of 0%; volatility of 107.92%; risk-free interest rate of 1.84%; and expected life of 2 years.

In conjunction with the completion of the Offering, Revive has entered into a letter of intent ("LOI") with Herman Holdings Limited ("HHL"), pursuant to which Revive and HHL will set up a new corporation ("JVCo").

(ii) On February 11, 2019, the Company completed the second tranche of the Offering. The second tranche of the Offering consisted of the sale of 3,050,000 Units, for the aggregate gross proceeds of both tranches of the Offering of \$1,401,000. The fair value of the Warrants issued in the second tranche of the Offering was estimated to be \$96,472 using a valuation model incorporating Black-Scholes on the following assumptions: dividend yield of 0%; volatility of 107.49%; risk-free interest rate of 1.77%; and expected life of 2 years. The Company incurred total transaction costs of \$13,490.

(iii) On March 18, 2020, the Company closed a private placement of 33,535,000 units ("Units") at a price of \$0.05 per Unit for gross proceeds of \$1,676,750 (the "Offering"). Hampton Securities Limited acted as sole lead agent (the "Agent") in connection with the Offering. Each Unit consists of one common share ("Share") in the capital of the Company and one common share purchase warrant ("Warrant"). Each Warrant entitles the holder thereof to acquire one common share of the Company at a price of \$0.07 per share at any time until March 18, 2023. The fair value of the Warrants was estimated to be \$704,235 using a valuation model incorporating Black-Scholes on the following assumptions: dividend yield of 0%; volatility of 139.73%; risk-free interest rate of 0.79%; and expected life of 3 years. The Company incurred total transaction costs of \$212,558 including \$150,908 cash commission to the Agent and a corporate finance fee of \$22,600. The Company also issued 3,018,150 non-transferrable broker warrants. Each broker warrant entitles the Agent to purchase one Unit of the Company (each a "Compensation Unit") at the price of \$0.05 per Unit at any time until March 18, 2022. Each Compensation Unit is comprised of one common share of the Company and one common share purchase warrant with each warrant exercisable into one common share of the Company at a price of \$0.07 per share at any time until March 18, 2023. The fair value of the broker warrants was estimated to be \$97,472 using a valuation model incorporating Black-Scholes on the following assumptions: dividend yield of 0%; volatility of 156.11%; risk-free interest rate of 0.69%; and expected life of 2 years.

(iv) On February 10, 2020, the Company issued 3,000,000 common shares valued at \$165,000 based on Revive's stock price on the date of issuance in consideration of 2,500,000 Red Light shares (note 7).

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

16. Share Capital (continued)

b) Common shares issued (continued)

(v) On April 14, 2020, the Company closed an additional 16,400,000 units ("Units") at a price of \$0.05 per Unit for gross proceeds of \$820,000 in connection with the closing of a second tranche of its brokered private placement financing (the "Offering"). Hampton Securities acted as sole lead agent (the "Agent") in connection with the Offering. Each Unit consists of one common share (each a "Share") in the capital of the Company and one common share purchase warrant (each a "Warrant"). Each Warrant entitles the holder thereof to acquire one common share of the Company (each a "Warrant Share") at a price of \$0.07 per Warrant Share at any time until April 14, 2023. The fair value of the Warrants was estimated to be \$377,200 using a valuation model incorporating Black-Scholes on the following assumptions: dividend yield of 0%; volatility of 144.75%; risk-free interest rate of 0.43%; and expected life of 3 years. The Company incurred total transaction costs of \$82,298 including \$73,800 cash commission to the Agent. Pursuant to the Offering, Revive issued the Agent and its sub-agents an aggregate of 1,476,000 non-transferable broker warrants (the "Broker Warrants"). Each Broker Warrant entitles the Agent and sub-agents to purchase one unit of the Company (each a "Compensation Unit") at the price of \$0.05 per Compensation Unit at any time until April 14, 2022. Each Compensation Unit is comprised of one common share in the capital of the Company and one common share purchase warrant (each a "Compensation Unit Warrant"). Each Compensation Unit Warrant shall entitle the holder thereof to purchase one common share in the capital of the Company (each a "Compensation Warrant Share") at a price of \$0.07 per Compensation Warrant Share at any time until April 14, 2023. The fair value of the broker warrants was estimated to be \$182,596 using a valuation model incorporating Black-Scholes on the following assumptions: dividend yield of 0%; volatility of 162.59%; risk-free interest rate of 0.37%; and expected life of 2 years.

(vi) On April 9, 2020, the Company issued 9,062,495 common shares valued at \$453,550 in settlement of accounts payable and accrued liabilities of \$453,550.

17. Warrants

The following table reflects the continuity of warrants for the years ended June 30, 2020 and 2019:

	Number of Warrants	Weighted Average Exercise Price
Balance, June 30, 2018	-	\$ -
Issued	14,010,000	0.15
Balance, June 30, 2019	14,010,000	\$ 0.15
Issued in private placements	49,935,000	0.07
Issued with convertible debenture	4,200,000	0.07
Exercised	(5,220,734)	0.15
Balance, June 30, 2020	62,924,266	\$ 0.08

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

17. Warrants (continued)

The following table reflects warrants issued and outstanding as at June 30, 2020:

Expiry Date and Description	Exercise Price (\$)	Fair Value (\$)	Number of Warrants Outstanding
February 4, 2021	0.15	182,222	7,010,000
February 8, 2021	0.15	96,472	1,779,266
February 5, 2025	0.07	25,348	4,200,000
March 18, 2023	0.07	704,235	33,535,000
April 14, 2023	0.07	377,200	16,400,000
Transaction costs		(262,493)	
	0.08	1,122,984	62,924,266

18. Broker and Finder Warrants

The following table reflects the continuity of broker and finder warrants for the years ended June 30, 2020 and 2019:

	Number of Broker Warrants	Weighted Average Exercise Price
Balance, June 30, 2018	-	\$ -
Issued	42,000	0.15
Balance, June 30, 2019	42,000	\$ 0.15
Issued	4,494,150	0.05
Exercised	(42,000)	0.15
Balance, June 30, 2020	4,494,150	\$ 0.05

The following table reflects broker and finder warrants issued and outstanding as at June 30, 2020:

Expiry Date	Exercise Price (\$)	Fair Value (\$)	Number of Broker Warrants Outstanding
March 18, 2022	0.05	97,472	3,018,150
April 14, 2022	0.05	182,596	1,476,000
	0.05	280,068	4,494,150

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

19. Stock Options

The Company has granted options for the purchase of common shares to its directors, officers, employees and certain consultants. The purpose of the plan is to attract, retain and motivate these parties by providing them with the opportunity, through share options, to acquire a proprietary interest in the Company and to benefit from its growth. These options are valid for a maximum of 10 years from the date of issue. Vesting terms and conditions are determined by the Board of Directors at the time of the grant. The maximum number of options to be issued under the plan shall not exceed 10% of the total number of common shares issued and outstanding.

The following table reflects the continuity of stock options for the years ended June 30, 2020 and 2019:

	Number of Stock Options	Weighted Average Exercise Price
Balance, June 30, 2018	3,470,375	\$ 0.42
Granted (v)(vi)(vii)	700,334	0.19
Balance, June 30, 2019	4,170,709	\$ 0.39
Cancelled	(1,450,000)	0.48
Granted (viii)(ix)(x)(xi)	10,375,000	0.20
Exercised	(850,000)	0.13
Balance, June 30, 2020	12,245,709	\$ 0.24

The following table reflects the actual stock options issued and outstanding as at June 30, 2020:

Expiry Date	Exercise Price (\$)	Weighted Average Remaining Contractual Life (years)	Number of Options Outstanding	Number of Options Vested (exercisable)	Grant Date Fair Value
July 9, 2023	0.30	3.02	40,375	40,375	9,270
January 31, 2024	0.66	3.59	215,000	215,000	96,775
February 10, 2025	0.60	4.62	500,000	500,000	186,518
April 10, 2027 (i)	0.28	6.78	565,000	565,000	124,553
November 1, 2022 (ii)	0.20	2.34	250,000	250,000	31,336
November 29, 2022 (iii)	0.325	2.42	100,000	100,000	26,368
August 21, 2023 (v)	0.205	3.14	75,000	75,000	9,887
October 11, 2020 (vi)	0.19	0.28	500,000	500,000	53,960
April 22, 2024 (vii)	0.17	3.81	125,334	125,334	14,193
December 27, 2029 (viii)	0.07	9.50	3,850,000	3,850,000	195,656
May 25, 2030 (x)	0.33	9.91	5,175,000	2,587,500	1,662,282
April 20, 2025 (xi)	0.125	4.81	850,000	850,000	94,214
			12,245,709	9,658,209	\$ 2,505,012

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements For the Years Ended June 30, 2020 and 2019 (Expressed in Canadian dollars)

19. Stock Options (continued)

(i) On April 10, 2017, the Company granted 965,000 stock options to certain officers, directors, employees and consultants of the Company at an exercise price of \$0.28 per share expiring on April 10, 2027. The fair value of the stock options was estimated to be \$212,732 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 119.21%; risk-free interest rates of 1.01%; and expected life of 4 years. 665,000 of these options vest as to one-half on the date of grant and one-half on the one year anniversary of the date of grant. The remaining 300,000 options vest as to one-third on the date of grant, one-third on the one year anniversary of the date of grant and one-third on the two year anniversary of the date of grant. During the year ended June 30, 2020, \$nil (2019 - \$1,238) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(ii) On November 1, 2017, the Company granted 250,000 stock options to a consultant of the Company at an exercise price of \$0.20 per share expiring on November 1, 2022. The fair value of the stock options was estimated to be \$31,336 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 114.34%; risk-free interest rates of 1.57%; and expected life of 5 years. These options vest as to one quarter (1/4) of the options on the date which is three (3) months from the date said options are granted, one quarter (1/4) of the options on the date which is six (6) months from the date of grant, one quarter (1/4) of the options on the date which is nine (9) months from the date of grant, and the final one quarter (1/4) of the options on the date which is twelve (12) months from the date of grant. During the year ended June 30, 2020, \$nil (2019 - \$3,580) were recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(iii) On November 29, 2017, the Company granted 350,000 stock options to a consultant of the Company at an exercise price of \$0.325 per share expiring on November 29, 2022. The fair value of the stock options was estimated to be \$92,289 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 115.58%; risk-free interest rates of 1.57%; and expected life of 5 years. These options vest as to one quarter (1/4) of the options on the date which is three (3) months from the date said options are granted, one quarter (1/4) of the options on the date which is six (6) months from the date of grant, one quarter (1/4) of the options on the date which is nine (9) months from the date of grant, and the final one quarter (1/4) of the options on the date which is twelve (12) months from the date of grant. During the year ended June 30, 2020, \$nil (2019 - \$14,679) was recorded as stock-based compensation in the consolidated statements of comprehensive loss. During the year ended June 30, 2020, 250,000 stock options were cancelled and as at June 30, 2020, 100,000 stock options remained outstanding.

(iv) On June 8, 2018, the Company granted 350,000 stock options to a consultant of the Company at an exercise price of \$0.205 per share expiring on June 8, 2023. The fair value of the stock options was estimated to be \$59,785 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 121.07%; risk-free interest rates of 2.11%; and expected life of 5 years. These options vest as to one quarter (1/4) of the options on the date which is three (3) months from the date said options are granted, one quarter (1/4) of the options on the date which is six (6) months from the date of grant, one quarter (1/4) of the options on the date which is nine (9) months from the date of grant, and the final one quarter (1/4) of the options on the date which is twelve (12) months from the date of grant. During the year ended June 30, 2020, \$nil (2019 - \$52,309) was recorded as stock-based compensation in the consolidated statements of comprehensive loss. During the year ended June 30, 2020, all of the 350,000 stock options were exercised.

(v) On August 21, 2018, the Company entered into a consulting agreement with a third-party and is committed to issue 25,000 stock options per month of services at a purchase price of \$0.205 which equates to a total of 75,000 stock options expiring August 21, 2023. The fair value of the stock options was estimated to be \$9,887 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 117.19%; risk-free interest rates of 2.18%; and expected life of 5 years. These options all vested during the year ended June 30, 2019. During the year ended June 30, 2020, \$nil (2019 - \$9,887) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements For the Years Ended June 30, 2020 and 2019 (Expressed in Canadian dollars)

19. Stock Options (continued)

(vi) On October 11, 2018, the Company granted, a consultant of the Company 500,000 stock options at an exercise price of \$0.19 per share expiring on October 11, 2020. The fair value of the stock options was estimated to be \$53,960 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 113.91%; risk-free interest rates of 2.27%; and expected life of 2 years. These options vest as to one-third on the date of grant, one-third on the one year anniversary of the date of grant and one-third on the two year anniversary of the date of grant. During the year ended June 30, 2020, \$16,616 (2019 - \$37,344) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(vii) On May 1, 2019, the Company granted, a consultant of the Company 125,334 stock options at an exercise price of \$0.17 per share expiring on April 22, 2024. The fair value of the stock options was estimated to be \$14,193 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 120.13%; risk-free interest rates of 1.56%; and expected life of 4.98 years. These options vest upon grant. During the year ended June 30, 2020, \$nil (2019 - \$14,193) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(viii) On December 27, 2019, the Company granted directors of the Company 3,850,000 options at an exercise price of \$0.07 per share expiring on December 27, 2029. The fair value of the stock options was estimated to be \$195,656 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 129.60%; risk-free interest rates of 1.62%; and expected life of 5 years. These options vested upon grant. During the year ended June 30, 2020, \$195,656 (2019 - \$nil) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(ix) On February 7, 2020, the Company granted a consultant of the Company 500,000 options at an exercise price of \$0.07 per share expiring on February 7, 2025. The fair value of the stock options was estimated to be \$27,886 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 131.53%; risk-free interest rates of 1.34%; and expected life of 5 years. These options vested upon grant. During the year ended June 30, 2020, \$27,886 (2019 - \$nil) was recorded as stock-based compensation in the consolidated statements of comprehensive loss. During the year ended June 30, 2020, all of the 500,000 stock options were exercised.

(x) On April 20, 2020, the Company granted a consultant of the Company 850,000 stock options at an exercise price of \$0.125 per share expiring on April 20, 2025. The fair value of the stock options was estimated to be \$94,214 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 141%; risk-free interest rates of 0.44%; and expected life of 5 years. These options vested upon grant. During the year ended June 30, 2020, \$94,214 (2019 - \$nil) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(xi) On May 25, 2020, the Company granted certain officers, directors, employees and consultants of the Company 5,175,000 stock options at an exercise price of \$0.33 per share expiring on May 25, 2030. The fair value of the stock options was estimated to be \$1,662,282 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 147.29%; risk-free interest rates of 0.36%; and expected life of 5 years. These options vest as to one half (1/2) of the options on the date of grant and one half (1/2) of the options on the date which is one (1) year from the date of grant. During the year ended June 30, 2020, \$856,948 (2019 - \$nil) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements For the Years Ended June 30, 2020 and 2019 (Expressed in Canadian dollars)

20. Net Loss per Common Share

The calculation of basic and diluted loss per share for the year ended June 30, 2020 was based on the loss attributable to common shareholders of \$5,381,687 (2019 - \$1,343,886) and the weighted average number of common shares outstanding of 106,877,828 (2019 - 63,969,666).

Diluted loss per share did not include the effect of 62,924,266 warrants (2019 - 14,010,000), 4,494,150 finder warrants (2019 - 42,000) and 12,245,709 stock options (2019 - 4,170,709) as they are anti-dilutive.

21. Income Taxes

Reconciliation of statutory tax rate

The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 26.5% (2019 - 26.5%) to the effective tax rate is as follows:

	Year ended June 30, 2020	Year ended June 30, 2019
Loss before recovery of income taxes	\$ (5,381,687)	\$ 1,343,886
Statutory tax rate	26.5%	26.5%
Expected income tax recovery	\$ (1,426,147)	\$ (356,130)
Share-based compensation and non-deductible expenses	634,954	43,601
Amounts booked directly into equity	(78,137)	(13,948)
Other permanent differences	26,943	-
Change in tax benefits not recognized	842,387	326,477
Income tax (recovery) expense	\$ -	\$ -

Unrecognized deferred tax assets

Deferred taxes are provided as a result of temporary differences that arise due to the differences between the income tax values and the carrying amount of assets and liabilities. Deferred tax assets have not been recognized in respect of the following deductible temporary differences:

	2020	2019
Property, plant and equipment	\$ 143	\$ 987
Intangible assets	26,711	26,711
Share issuance costs	86,383	29,842
Non-capital losses carried forward	3,330,835	2,675,970
Investments	131,838	-
Other temporary difference	3,207	3,220
	\$ 3,579,117	\$ 2,736,730
Less: deferred tax assets not recognized	(3,579,117)	(2,736,730)
Net deferred tax assets	\$ -	\$ -

Revive Therapeutics Ltd.
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

21. Income Taxes (continued)

As at June 30, 2020 and 2019, the Company had a 100% valuation allowance against its deferred income tax balances as it is not considered probable that sufficient future tax profit will allow the deferred tax assets to be realized.

Share issuance costs will be fully amortized in 2024. Intangible assets and other temporary differences may be carried forward indefinitely.

The Company's Canadian non-capital income tax losses expire as noted in the table below:

2031	5,664
2032	107,704
2033	138,113
2034	545,679
2035	1,851,509
2036	2,715,262
2037	1,691,703
2038	1,746,802
2039	1,295,564
2040	<u>2,471,190</u>
	<u>12,569,190</u>

22. Related Party Balances and Transactions and Major Shareholders

(a) Related party balances and transactions:

Related parties include the directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.

Year Ended June 30,	2020	2019
Marrelli Support Services Inc. ("Marrelli Support") (i)	\$ 49,412	\$ 49,921
DSA Corporate Services Inc. and DSA Filing Services Limited (together, known as "DSA") (ii)	\$ 39,702	\$ 21,549

(i) The Company owed Marrelli Support \$2,352 as at June 30, 2020 (June 30, 2019 - owed \$2,390) for the services of Carmelo Marrelli to act as Chief Financial Officer ("CFO") of the Company. This amount was included in accounts payable and accrued liabilities. The Company has entered into a consulting agreement (the "Marrelli Consulting Agreement") with Marrelli Support and Mr. Marrelli to provide the services of Mr. Marrelli as CFO of the Company. The term of the Marrelli Consulting Agreement commenced on July 14, 2013, and shall continue until terminated by either Mr. Marrelli or the Company. Pursuant to the Marrelli Consulting Agreement, Mr. Marrelli is entitled to receive monthly compensation of \$1,250 per month, and incentive stock option grants on a reasonable basis, consistent with the grant of options to other grantees. In addition, Marrelli Support provides bookkeeping services to the Company. Mr. Marrelli is the Managing Director of Marrelli Support. The amounts charged by Marrelli Support are based on what Marrelli Support usually charges its clients. The Company expects to continue to use Marrelli Support for an indefinite period of time.

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements For the Years Ended June 30, 2020 and 2019 (Expressed in Canadian dollars)

22. Related Party Balances and Transactions and Major Shareholders (continued)

(a) Related party balances and transactions (continued):

(ii) The Company owed DSA \$4,603 as at June 30, 2020 (June 30, 2019 - \$1,293) for corporate secretarial and filing services. This amount was included in accounts payable and accrued liabilities. DSA consists of two private companies beneficially controlled by Carmelo Marrelli, the CFO of the Company. Services were incurred in the normal course of operations for corporate secretarial, electronic filing and news dissemination services. The Company expects to continue to use DSA's services for an indefinite period of time.

(b) Remuneration of directors and key management personnel including Chief Executive Officer and Chief Financial Officer of the Company for the years ended June 30, 2020 and 2019 was as follows:

<u>Year Ended June 30,</u>	<u>2020</u>	<u>2019</u>
Stock-based compensation	\$ 774,007	\$ -
Consulting fees	\$ 382,859	\$ 17,430
Salaries and benefits - former President and CEO	\$ 125,000	\$ 500,000

(c) Major shareholders:

As at June 30, 2020, no person or corporation beneficially owns or exercises control or direction over common shares of the Company carrying more than 10% of the voting rights attached to all of the common shares of the Company.

None of the Company's major shareholders have different voting rights other than holders of the Company's common shares.

The Company is not aware of any arrangements, the operation of which may at a subsequent date result in a change in control of the Company. The Company is not directly or indirectly owned or controlled by another corporation, by any government or by any natural or legal person severally or jointly.

23. Commitments and Contingency

The Company has also entered into a licensing arrangement with South Carolina Research Foundation and Wisconsin Alumni Research Foundation, whereby certain milestone payments and royalties are payable upon the achievement of certain events. The Company will record these amounts as the events occur. The arrangement with South Carolina Research Foundation specifies minimum annual royalty payments as follows: due on or before January 1, 2021 - USD \$7,500; due on or before January 1, 2022 and each anniversary thereafter - USD \$10,000.

Contingency

The Company is in dispute with a supplier over invoices in the amount of \$827,574 plus interest for which the supplier has sought arbitration. The dispute is in arbitration. No provision has been set up in the accounts of the Company. Any settlement and/or payment will be accounted for in the year it occurs. Readers are cautioned that the eventual resolution of this liability will be based on additional information and the occurrence of future events.

Revive Therapeutics Ltd.

Notes to Consolidated Financial Statements
For the Years Ended June 30, 2020 and 2019
(Expressed in Canadian dollars)

24. Office Expenses

	2020	2019
Reporting issuer costs	\$ 95,259	\$ 50,263
Administrative	451,750	16,290
Insurance	53,418	32,475
Travel and accommodation	11,160	1,958
Meals and entertainment	3,193	2,097
Bank charges	3,164	2,542
Interest income	(1,057)	(6,027)
	\$ 616,887	\$ 99,598

25. Subsequent Events

On August 6, 2020, the Company granted 6,000,000 stock options to an officer of the Company.

On August 12, 2020, the Company granted 4,000,000 stock options to certain consultants.

On August 24, 2020, the Company granted 300,000 stock options to a consultant.

Subsequent to June 30, 2020, 36,182,896 warrants were exercised for gross proceeds of \$2,943,944; 2,579,632 broker warrants were exercised for gross proceeds of \$128,982 and 700,000 stock options were exercised for gross proceeds of \$109,000.